How much is Mounjaro on the NHS — and who qualifies right now?

You've looked into NHS Mounjaro and hit a wall — here's why

You've spoken to your GP, or you've read that Mounjaro is coming to the NHS, and somehow it still isn't available to you. That's not unusual, and it's not a mistake. The NHS rollout is phased by design, tied to NICE's technology appraisal TA1026 published in December 2024, which restricts which patients qualify at each stage.

As of mid-2026, the NHS is dispensing Mounjaro only to adults with a BMI of 40 or above who also have four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That's a high bar deliberately. The second NHS cohort, covering BMI 35–39.9 with the same four conditions, began activating in June 2026. Lower thresholds apply for some ethnic backgrounds under UK guidance. Even if you tick every box, GP participation in the new prescribing scheme is optional, so availability varies by practice and area. The NHS is also explicit that meeting the criteria doesn't guarantee access, patients must engage with wrap-around diet and activity support.

Worth doing in the next sixty seconds: NICE's published recommendations for tirzepatide list the cohort criteria clearly. Check whether your BMI and conditions put you in a current or future cohort before assuming the door is closed permanently.

What 'free on the NHS' actually means in practice

If you do qualify and your GP practice is participating, Mounjaro is dispensed on an NHS prescription. You pay the standard prescription charge (currently £9.90 per item in England, or nothing if you hold an exemption certificate) rather than the full cost of the medicine. That's the sense in which it's free or near-free. Scotland, Wales and Northern Ireland have their own arrangements. The detail of what NHS patients actually pay depends on where you live and your exemption status.

For the people who don't qualify yet, the alternative is a private prescription from a regulated prescriber. UK private pricing for Mounjaro has moved considerably since Eli Lilly revised its list price upward from 1 September 2025, the highest-dose pen's list price rose from around £122 to around £330, and private providers have repriced accordingly. Typical private costs range roughly £149 to £375 per four-week pen depending on the dose and the service, as widely reported following Lilly's announcement. If you want to understand what Mounjaro costs on the NHS compared to going privately, that context helps explain why so many people are weighing up both routes. A fuller breakdown of private Mounjaro pricing by dose sets out what drives the variation.

The honest context: lower doses (which is where everyone starts) sit toward the lower end of that range. The starter pen is a tolerability dose; its job is settling your system, not delivering the full therapeutic effect. Most patients who reach higher doses have been on treatment for several months and have seen real change by then.

What private price comparisons usually miss

Headline prices quoted by online providers don't always include everything. A consultation fee, a separate prescription charge, delivery costs and any aftercare calls can each add to the figure you see. Some services bill monthly subscriptions whether or not your dose needs changing. If you're comparing where to buy Mounjaro privately, the real question is what's inside the price, not just the number on the page.

At nume, one price covers the consultation, the prescription, the treatment itself, tracked next-working-day delivery and 7-day priority aftercare. There are no subscriptions and no auto-renewals. Every repeat order goes back to a named prescriber for review, a real clinician checks the file, not a renewal algorithm. We're not the cheapest option out there, and that's a deliberate choice. Our approach is built around clinical safety and service, not competing on margin.

You can verify any online pharmacy in about thirty seconds on the GPhC pharmacy register. If a provider isn't listed, don't order from them. Fake Mounjaro pens are a real and documented problem in the UK, the MHRA has warned publicly about counterfeit weight-loss injections, and some seized fakes have contained insulin. A pharmacy you can't verify is a risk not worth taking for a Prescription-Only Medicine.

Why 'cheapest' is the wrong question when it's a prescription medicine

Price matters, but it's the wrong starting point for a POM. The right questions are: is this a GPhC-registered pharmacy, is a qualified prescriber reviewing my case, and is the medicine coming through the licensed UK supply chain? A small saving on the pen price means nothing if the medicine is counterfeit or the 'consultation' is a checkbox exercise. Mounjaro's clinical profile (the dual GIP and GLP-1 mechanism, the SURMOUNT trial results, the titration schedule) is only relevant if you're taking the genuine, correctly stored medicine under proper clinical oversight.

The NHS England guidance on weight-management injections makes the same point from a patient-safety angle: clinical assessment, not price, is the foundation of safe treatment. That's as true for private routes as it is for NHS ones.

If you want to find out whether you're eligible for private treatment through nume, the consultation is free. Check your eligibility and a prescriber will review your case the same day.